Tag results:

cell reprogramming

NaV1.5 Knockout in iPSCs: A Novel Approach to Study NaV1.5 Variants in a Human Cardiomyocyte Environment

[Scientific Reports] Scientists developed a homozygous NaV1.5 KO iPSC line able to differentiate into cardiomyocytes with CRISPR/Cas9 tool. The NaV1.5 KO iPSC-cardiomyocytes exhibited an organized contractile apparatus, spontaneous contractile activity, and electrophysiological recordings confirmed the major reduction in total Na+ currents.

Restoring Mammary Gland Structures and Functions with Autogenous Cell Therapy

[Biomaterials] In vitro chemical induction with RepSox generated chemically induced mammary epithelial cells (CiMECs) with milk secreting functions from goat ear fibroblasts (GEFs). Single-cell RNA sequencing revealed that during the reprogramming process, GEFs may have sequentially undergone embryonic ectoderm-like and different MEC developmental states.

Chromatin lncRNA Platr10 Controls Stem Cell Pluripotency by Coordinating an Intrachromosomal Regulatory Network

[Genome Biology] Scientists used a novel chromatin RNA in situ reverse transcription sequencing approach to profile long noncoding RNAs in the Oct4 promoter.

DMRT1-Mediated Reprogramming Drives Development of Cancer Resembling Human Germ Cell Tumors with Features of Totipotency

[Nature Communications] Tumor-derived iPSCs were able to contribute to non-neoplastic somatic cells in adult mice. Mechanistically, DMRT1, which was expressed in primordial germ cells, drove the reprogramming and propagation of the tumor cells in vivo.

Reprogramming Glial Cells into Functional Neurons for Neuro-Regeneration: Challenges and Promise

[Neuroscience Bulletin] Scientists extensively review the experimental findings of the direct conversion of glial cells to neurons in vitro and in vivo and discuss the remaining issues and challenges related to the glial subtypes and the specificity and efficiency of direct cell-reprograming, as well as the influence of the microenvironment.

Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

[Brooklyn ImmunoTherapeutics, Inc.] Brooklyn ImmunoTherapeutics, Inc. has announced that it had completed its acquisition of Novellus Therapeutics Limited. Novellus is developing next‑generation engineered MSC therapies using extensively patented mRNA-based cell reprogramming and gene editing technologies.

Popular